This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Flurbiprofen oromucosal


Oral lozenges containing flurbiprofen

Drugs List

  • flurbiprofen 8.75mg lozenge
  • Therapeutic Indications


    Relief of sore throat


    It is recommended that this medication should be used for a maximum of three days.


    One lozenge to be sucked or dissolved slowly in the mouth every three to six hours as required. Maximum five lozenges in a 24 hour period.


    One lozenge to be sucked or dissolved slowly in the mouth every three to six hours as required. Maximum five lozenges in a 24 hour period.


    Children over 12 years
    One lozenge to be sucked or dissolved slowly in the mouth every three to six hours as required. Maximum five lozenges in a 24 hour period.

    Patients with Renal Impairment

    Use with caution.

    NSAIDs have been reported to cause nephrotoxicity in various forms. In patients with renal impairment, the use of NSAIDs such as flurbiprofen lozenges may result in the deterioration of renal function.

    Patients with Hepatic Impairment

    Use with caution.

    In patients with hepatic impairment, the use of NSAIDs such as flurbiprofen lozenges may result in the deterioration of renal function.

    Additional Dosage Information

    To avoid local irritation, flurbiprofen lozenges should be moved around the mouth whilst sucking.


    Children under 12 years
    Predisposition to haemorrhage
    Hereditary fructose intolerance
    History of gastrointestinal bleeding
    History of gastrointestinal perforation
    History of peptic ulcer
    Nasal polyps, angioedema, and bronchospastic reactivity to NSAIDs
    Peptic ulcer
    Severe cardiac failure
    Severe hepatic impairment
    Severe renal impairment
    Third trimester of pregnancy

    Precautions and Warnings

    Allergic disposition
    Cardiac failure
    Connective tissue disorder
    Crohn's disease
    First trimester of pregnancy
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of asthma
    History of bronchospasm
    History of cardiac failure
    History of coagulopathy
    History of gastrointestinal disorder
    History of urticaria
    Renal impairment
    Second trimester of pregnancy
    Systemic lupus erythematosus
    Ulcerative colitis

    NSAIDs may provoke or exacerbate asthma
    Contains glucose
    Preparation contains sucrose
    The lozenge should be moved around the mouth whilst sucking
    Discontinue if signs of gastro-intestinal bleeding occur
    May cause bronchospasm
    Discontinue if rash with systemic, allergic or mucosal symptoms occurs
    Discontinue if symptoms of peptic ulcer occur
    Start treatment at lowest recommended dose
    Advise patients to avoid aspirin and NSAID use
    Consult doctor if symptoms persist or treatment is required for > 3 days

    Pregnancy and Lactation


    Flurbiprofen is contraindicated in the last trimester of pregnancy and should be used with caution in the first two trimesters of pregnancy.

    Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that shares the same precautions for human pregnancy use as other NSAIDs. No teratogenic effects were observed in mice, rats and rabbits administered this drug during gestation.

    Like other NSAIDs, systemic use of flurbiprofen in rats has been associated with prolonged gestations, foetal growth retardation, and decreased foetal survival. In one study of pregnant rats, flurbiprofen inhibition of parturition appeared to be dose-related.

    No reports describing the use of flurbiprofen during human pregnancy have been located. Flurbiprofen has a short plasma elimination half-life (5.7 hours) but other factors, such as its toxicity profile, need to be considered.

    Regular use of NSAIDs during the third trimester of pregnancy may result in the premature closure of the foetal ductus arteriosus in utero and persistent pulmonary hypertension of the newborn and may cause prolonged gestation, dystocia and delayed parturition.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use flurbiprofen with caution in breastfeeding.

    Flurbiprofen appears in the breast milk in very low concentrations and is unlikely to affect the breast-fed infant adversely.

    The small amounts of flurbiprofen recovered from transitional and mature breast milk seem to indicate that the risk posed by flurbiprofen to a nursing infant is slight, if it exists at all.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Acute renal failure (reversible)
    Allergic reaction
    Aplastic anaemia
    Arterial thrombosis
    Aseptic meningitis
    Blood disorders
    Buccal irritation
    Bullous reactions
    Cardiac failure
    Epidermal necrolysis
    Erythema multiforme
    Exacerbation of pre-existing asthma
    Fluid retention
    Gastro-intestinal ulceration and bleeding
    Hearing disturbances
    Hepatic impairment
    Hypersensitivity reactions
    Mouth ulcers
    Myocardial infarction
    Papillary necrosis
    Peptic ulceration
    Stevens-Johnson syndrome
    Taste disturbances
    Ulcerative stomatitis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2016

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary. 70th ed. London: BMJ Group and Pharmaceutical Press; 2015.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    Paediatric Formulary Committee. BNF for Children 2015-2016. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2015.

    Summary of Product Characteristics: Strefen Honey and Lemon lozenge. Reckitt Benckiser Healthcare (UK) Ltd. Revised November 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.